Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1440145
European Journal of Endocrinology, Vol 144, Issue 2, 145-154
Copyright © 2001 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lameloise, N
Right arrow Articles by Burger, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lameloise, N
Right arrow Articles by Burger, A
Articles

Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy

N Lameloise, C Siegrist-Kaiser, M O'Connell, and A Burger

Thyroid Unit, Division of Endocrinology and Metabolism, Department of Medicine, University of Geneva, CH 1211 Geneva 4, Switzerland.

OBJECTIVE: We earlier reported marked qualitative differences between the effect of 3,5,3'-tri-iodothyroacetic acid (Triac) and tri-iodothyronine (T3) on cardiac hypertrophy at equivalent thyroid-stimulating hormone (TSH)-suppressive doses. We have now extended these studies to specific cardiac parameters. Due to its rapid metabolic clearance rate, Triac is not suitable for TSH suppression and therefore the slowly metabolized 3,5,3',5'-tetraiodothyroacetic acid (Tetrac), the precursor of Triac, was studied. METHODS: Hypothyroid rats were infused over 13 days with 1.5-40.5 nmol Tetrac/day per 100 g body weight (BW) or with 0.5-13.5 nmol thyroxine ((4)T4)/day per 100 g BW. RESULTS: The responses of serum TSH and of hepatic monodeiodinase type 1 were parallel for both hormones, their potency ratios could therefore be compared. Tetrac was revealed as being only half as active on hepatic monoiodinase type 1 despite a similar serum TSH levels. Tetrac can therefore be considered to have a preferential action on serum TSH suppression. The cardiac effects on Ca2+-ATPase (SERCA 2a) and monodeiodinase type 1 activity were qualitatively different and therefore one cannot give an overall quantitative estimate of these differences. The results showed clearly, however, that Tetrac is less efficient for all parameters studied, namely induction of cardiac hypertrophy, alpha-myosin heavy chain mRNA, monodeiodinase type 1 activity and mRNA levels of the sarcoplasmic SERCA 2a. CONCLUSION: We postulate therefore that, in the rat and possibly in man, Tetrac could represent a favorable alternative for suppression of serum TSH levels.


This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
G. J. Kahaly and W. H. Dillmann
Thyroid Hormone Action in the Heart
Endocr. Rev., August 1, 2005; 26(5): 704 - 728.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 European Society of Endocrinology.